141 related articles for article (PubMed ID: 16732904)
21. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
22. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Takagi K; Kobayashi M; Ikeda K; Kumada H
J Gastroenterol; 2004 Jan; 39(1):34-40. PubMed ID: 14767732
[TBL] [Abstract][Full Text] [Related]
23. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
Ciancio A; Smedile A; Rizzetto M; Lagget M; Gerin J; Korba B
Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
[TBL] [Abstract][Full Text] [Related]
24. [Quasispecies and mutation of hepatitis B virus polymerase gene in lamivudine- treated patients].
Huang YP; Wang YM; Lan L; Fan Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):235-8. PubMed ID: 12716526
[TBL] [Abstract][Full Text] [Related]
25. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
[TBL] [Abstract][Full Text] [Related]
26. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
Hsu CW; Yeh CT; Chang ML; Liaw YF
Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
[TBL] [Abstract][Full Text] [Related]
27. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
Pichkovskaia VA; Fevraleva IS; Ibragimova MM; Solov'eva TI; Drel' PE; Sudarikov AB
Mol Gen Mikrobiol Virusol; 2004; (1):27-9. PubMed ID: 15025001
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
Song SJ; Zhuang H; Yan J; Wei HS; He ZP; Song C; Dong QM; Xiao YP
Zhonghua Yu Fang Yi Xue Za Zhi; 2005 May; 39(3):203-5. PubMed ID: 15938857
[TBL] [Abstract][Full Text] [Related]
29. A PCR-RFLP based protocol for the detection of hepatitis B virus variants in some lamivudine-untreated chronic hepatitis B virus carriers in Pakistan.
Tauseef I; Iqbal F; Rehman W; Ali M; Qureshi JA; Aslam MA
Pak J Pharm Sci; 2012 Apr; 25(2):349-52. PubMed ID: 22459460
[TBL] [Abstract][Full Text] [Related]
30. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
[TBL] [Abstract][Full Text] [Related]
31. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
Yeh CT; Chien RN; Chu CM; Liaw YF
Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
[TBL] [Abstract][Full Text] [Related]
32. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
33. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
[TBL] [Abstract][Full Text] [Related]
34. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
35. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.
Li MW; Hou W; Wo JE; Liu KZ
J Zhejiang Univ Sci B; 2005 Jul; 6(7):664-7. PubMed ID: 15973769
[TBL] [Abstract][Full Text] [Related]
36. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection.
Shi M; Yang ZJ; Wang RS; Zhang H; Zhu YF; Xu YP; Lin QY; Jin LJ
Clin Chim Acta; 2006 Nov; 373(1-2):172-5. PubMed ID: 16814763
[TBL] [Abstract][Full Text] [Related]
37. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
39. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
[TBL] [Abstract][Full Text] [Related]
40. [Mutation patterns in the RT region of hepatitis B virus P gene in patients treated with nucleoside/nucleotide analogs].
DENG J; ZHANG DH; YU DM; CHEN L; ZHANG XX
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):342-5. PubMed ID: 19497198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
